drugset / Trial / NCT07095023
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
Recruiting
112 enrolled
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Affiliated Cancer Hospital of Shantou University Medical College · collabCancer Hospital of Guangxi Medical University · collabFirst Affiliated Hospital of Wenzhou Medical University · collabGuangdong Women and Children Hospital · collabHainan People's Hospital · collabNanfang Hospital, Southern Medical University · collabPeking University Cancer Hospital & Institute · collabPeking University Shenzhen Hospital · collabThe Affiliated Hospital Of Guizhou Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of oral paclitaxel plus fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in the neoadjuvant treatment of HER2+ breast cancer patients.
Timeline
- Start
- 2025-08-15
- Primary completion
- 2026-12-30
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | Oral |
| Subject | Pertuzumab | Monoclonal antibody | 600 mg | Subcutaneous |
| Subject | Trastuzumab | Monoclonal antibody | 600 mg | Subcutaneous |